Anti-S protein [P17]

Absolute Antibody

Anti-S protein [P17]

9

The specificity of the antibody was confirmed by ELISA analysis (EC50 = 29 pM). Surface plasmon resonance (SPR) assays demonstrated that the antibody bound to SARS-CoV-2 RBD with a high affinity of 96 pM. Immunofluorescence staining showed that the antibody prevented SARS-CoV-2 infection in a dosedependent manner in Vero cells. Pseudovirus neutralization assay (PSV) in Huh7 cells and standard 50% plaque reduction neutralization tests (PRNT) in Vero cells, both showed that the antibody exhibited stronger neutralizing activity with IC50 and PRNT50 values of 165 and 195 pM, respectively. The antibody conferred effective protection in animal models. The structure of the Fab fragment and a prefusion stabilized SARSCoV-2 S ectodomain trimer was characterized using single-particle cryo-EM. The antibody was employed together with H014 to develop a therapeutic antibody cocktail against SARS-CoV-2 with neutralizing properties (Yao et al., 2021; PMID: 33262452).

ImmunoFluorescence, ELISA, Neutralisation/Blocking, Other Application

Research Use Only

Monoclonal

P17

S

surface glycoprotein

GU280_gp02, spike glycoprotein, surface glycoprotein

Human

IgG1

Spike glycoprotein

Virus

-20°C,2°C to 8°C

41116161